<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font20 { font-size : 20; } .font22 { font-size : 22; } .font23 { font-size : 23; } .font25 { font-size : 25; } .font31 { font-size : 31; }</style>
 <body>
  <p>
   <span class="font31">migraine </span>
   <span class="font25">pediatric </span>
   <span class="font23">patients </span>
   <span class="font23">headache </span>
   <span class="font22">treatment </span>
   <span class="font20">efficacy </span>
   <span class="font18">children </span>
   <span class="font18">frequency </span>
   <span class="font18">study </span>
   <span class="font17">propranolol </span>
   <span class="font16">topiramate </span>
   <span class="font15">amitriptyline </span>
   <span class="font15">prophylaxis </span>
   <span class="font15">{border-style </span>
   <span class="font15">clinical </span>
   <span class="font15">studies </span>
   <span class="font15">chronic </span>
   <span class="font15">effects </span>
   <span class="font15">px;} </span>
   <span class="font14">#ffffff;} </span>
   <span class="font14">attacks </span>
   <span class="font14">group </span>
   <span class="font14">placebo </span>
   <span class="font14">reduction </span>
   <span class="font14">significant </span>
   <span class="font14">use </span>
   <span class="font14">&amp;lt; </span>
   <span class="font14">Neurol. </span>
   <span class="font14">migraine. </span>
   <span class="font14">trial </span>
   <span class="font14">adolescents </span>
   <span class="font14">age </span>
   <span class="font14">compared </span>
   <span class="font14">drugs </span>
   <span class="font14">prophylactic </span>
   <span class="font14">showed </span>
   <span class="font14">therapy </span>
   <span class="font13">Headache </span>
   <span class="font13">Headache. </span>
   <span class="font13">flunarizine </span>
   <span class="font13">randomized </span>
   <span class="font13">treated </span>
   <span class="font13">trials </span>
   <span class="font13">controlled </span>
   <span class="font13">data </span>
   <span class="font13">safety </span>
   <span class="font13">used </span>
   <span class="font12">mg/kg/day) </span>
   <span class="font12">pharmacological </span>
   <span class="font12">results </span>
   <span class="font12">weight </span>
   <span class="font12">childhood </span>
   <span class="font12">drug </span>
   <span class="font12">effective </span>
   <span class="font12">intensity </span>
   <span class="font12">migraine: </span>
   <span class="font12">monthly </span>
   <span class="font12">preventive </span>
   <span class="font12">primary </span>
   <span class="font12">rate </span>
   <span class="font12">Cephalalgia. </span>
   <span class="font12">Child </span>
   <span class="font12">Neurol </span>
   <span class="font12">children. </span>
   <span class="font12">considered </span>
   <span class="font12">dose </span>
   <span class="font12">groups </span>
   <span class="font12">included </span>
   <span class="font12">mg/day </span>
   <span class="font12">mg/day) </span>
   <span class="font12">plus </span>
   <span class="font12">published </span>
   <span class="font12">px; </span>
   <span class="font12">retrospective </span>
   <span class="font12">{font-family </span>
   <span class="font12">appetite, </span>
   <span class="font12">combined </span>
   <span class="font12">conducted </span>
   <span class="font12">font-size </span>
   <span class="font12">increased </span>
   <span class="font12">main </span>
   <span class="font12">mg/day), </span>
   <span class="font12">migraine, </span>
   <span class="font12">migraineurs </span>
   <span class="font12">month </span>
   <span class="font12">observed </span>
   <span class="font12">reducing </span>
   <span class="font12">response </span>
   <span class="font12">valproate </span>
   <span class="font12">years </span>
   <span class="font11">./head. </span>
   <span class="font11">./j.-...x </span>
   <span class="font11">./s--- </span>
   <span class="font11">CHAMP </span>
   <span class="font11">Migraine </span>
   <span class="font11">Papetti </span>
   <span class="font11">Propranolol </span>
   <span class="font11">attack </span>
   <span class="font11">behavioral </span>
   <span class="font11">days </span>
   <span class="font11">double; </span>
   <span class="font11">effect </span>
   <span class="font11">frequent </span>
   <span class="font11">high </span>
   <span class="font11">history </span>
   <span class="font11">pain </span>
   <span class="font11">patients, </span>
   <span class="font11">prevention </span>
   <span class="font11">randomized, </span>
   <span class="font11">reduced </span>
   <span class="font11">significantly </span>
   <span class="font11">treatments </span>
   <span class="font11">(%) </span>
   <span class="font11">.), </span>
   <span class="font11">Amitriptyline </span>
   <span class="font11">Fallah </span>
   <span class="font11">Flunarizine </span>
   <span class="font11">Hershey </span>
   <span class="font11">Italy </span>
   <span class="font11">Kim </span>
   <span class="font11">adverse </span>
   <span class="font11">age. </span>
   <span class="font11">available </span>
   <span class="font11">biofeedback </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">differences </span>
   <span class="font11">disability </span>
   <span class="font11">duration </span>
   <span class="font11">evidence </span>
   <span class="font11">gain </span>
   <span class="font11">higher </span>
   <span class="font11">lack </span>
   <span class="font11">mg/kg/day </span>
   <span class="font11">non-pharmacological </span>
   <span class="font11">open </span>
   <span class="font11">population </span>
   <span class="font11">sodium </span>
   <span class="font11">solid; </span>
   <span class="font11">therapeutic </span>
   <span class="font11">tolerability </span>
   <span class="font11">treatment, </span>
   <span class="font11">years. </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font11">.). </span>
   <span class="font11">CBT </span>
   <span class="font11">However, </span>
   <span class="font11">Iran </span>
   <span class="font11">LeCates </span>
   <span class="font11">Med </span>
   <span class="font11">Pizotifen </span>
   <span class="font11">Slater </span>
   <span class="font11">Topiramate </span>
   <span class="font11">University </span>
   <span class="font11">adolescent </span>
   <span class="font11">adult </span>
   <span class="font11">amitriptyline, </span>
   <span class="font11">article </span>
   <span class="font11">associated </span>
   <span class="font11">bold </span>
   <span class="font11">botulinum </span>
   <span class="font11">cinnarizine </span>
   <span class="font11">coenzyme </span>
   <span class="font11">cognitive </span>
   <span class="font11">complex </span>
   <span class="font11">concerning </span>
   <span class="font11">courier; </span>
   <span class="font11">depression </span>
   <span class="font11">dizziness, </span>
   <span class="font11">double-blind </span>
   <span class="font11">double-blind, </span>
   <span class="font11">effectiveness </span>
   <span class="font11">em; </span>
   <span class="font11">evaluated </span>
   <span class="font11">ginkgolide </span>
   <span class="font11">headaches </span>
   <span class="font11">improvement </span>
   <span class="font11">insomnia </span>
   <span class="font11">label </span>
   <span class="font11">licensed </span>
   <span class="font11">months </span>
   <span class="font11">months, </span>
   <span class="font11">multicenter </span>
   <span class="font11">number </span>
   <span class="font11">patients) </span>
   <span class="font11">pizotifen </span>
   <span class="font11">placebo-controlled </span>
   <span class="font11">pt;} </span>
   <span class="font11">ranging </span>
   <span class="font11">received </span>
   <span class="font11">recent </span>
   <span class="font11">respectively. </span>
   <span class="font11">responder </span>
   <span class="font11">score </span>
   <span class="font11">shown </span>
   <span class="font11">terms </span>
   <span class="font11">therapies </span>
   <span class="font11">topiramate, </span>
   <span class="font11">weeks </span>
   <span class="font11">years), </span>
   <span class="font11">younger </span>
  </p>
 </body>
</html>
